- Home
- About
- Team
- Today's Market
- Premium
- Research it
- Outlook
- Portfolio
- Mobile
- Trust Equitymaster
- Help
- Free Reports
MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Stock Quote
- JAGSON PHAR
JAGSON PHAR Share Price 
(JSPH)
Here is the latest stock price and chart of JAGSON PHAR. For a sector overview, read our pharmaceuticals sector report.
| Live BSE Quotes | Aug 21, 2018 (Close) | ||
|---|---|---|---|
| Price (Rs)27.65 | Open (Rs) 28.50 | High (Rs) 28.50 | Low (Rs) 27.10 |
| % Change-0.18 | Volume 712 | Value (Rs) 19,441 | 52-Week H/L 47.00 / 22.20 |
| Live NSE Quotes | Aug 21, 2018 (Close) | ||
|---|---|---|---|
| Price (Rs)27.50 | Open (Rs) 27.70 | High (Rs) 27.75 | Low (Rs) 27.05 |
| % Change1.10 | Volume 8,899 | Value (Rs) 244,545 | 52-Week H/L 46.90 / 22.40 |
| BSE Sensex | CNX Nifty |
- Charts
-
PERIOD - Advanced Charts new
- Charts by TradingView
JAGSON PHAR Share Price Today:
JAGSON PHAR last traded price was down 0.2% to Rs 27.7 on the BSE. On the NSE, JAGSON PHAR last traded price was up 1.1% to Rs 27.5. The total volume of shares traded was 0.0 m.
Overall, the broader S&P BSE HEALTHCARE Index was up by 1.1%. And the benchmark S&P BSE SENSEX was at 38,285.8 (up 0.0%).
Over the last 30 days, the JAGSON PHAR share price is up 18.2%. And over the last one year, JAGSON PHAR share price is down 10.8%.
|
| |
Today's Market
Sensex, Nifty Close at Record Highs; Healthcare and Power Stocks Witness Buying(Closing)
Indian share markets continued to trade on a flat during closing hours of trade and ended the day marginally higher to close at fresh record high levels.
Related Views On News
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
Shalby Ltd. (IPO)
Dec 2, 2017Should you subscribe to the IPO of Shalby Ltd?
The Power of 5 Minutes (The 5 Minute Wrapup)
Jun 16, 2017Here's what you can expect from The 5 Minute Wrapup in the coming months and years.
Eris Lifesciences Limited (IPO)
Jun 15, 2017Exposure to high margin specialty products offers promising growth prospects.
Laurus Labs Ltd (IPO)
Dec 6, 2016Equitymaster analyses Initial Public Offering (IPO) of Laurus Labs, one of the leading supplier of APIs for ARVs and Hepatitis C.
More Views on NewsMost Popular
3 Reasons Why I Believe This Company Can Make It Big!(The 5 Minute Wrapup)
Aug 16, 2018How consumer-facing businesses can multiply your wealth in the coming years.
Trading in These Times: 8% Gains in 3 Days!(Profit Hunter)
Aug 9, 2018Here are 2 stocks you can buy right now! And there are plenty more opportunities to come...
Economic Growth was Faster During Manmohan Years Than Modi Years, But...(Vivek Kaul's Diary)
Aug 20, 2018When it comes to the economy, both Modi and Manmohan have had their share of major screw ups.
Why HDFC Equity Fund Disappointed Its Investors(Outside View)
Aug 9, 2018Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.
To Identify Pricing Power, Compare Companies Like This(Chart Of The Day)
Aug 10, 2018Pricing power is the first tenet of an economic moat. If you see that in a company, do investigate to find an economic moat.
MoreTRACK JAGSON PHAR
- Track your investment in JAGSON PHAR with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
OTHER USEFUL LINKS
MARKET STATS
|
| |
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.